rs199673455 — GPD1

Pathogenic missense variant in glycerol-3-phosphate dehydrogenase 1; homozygous or compound heterozygous loss causes transient infantile hypertriglyceridemia with hepatomegaly and fatty liver

See your personal result for GPD1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

GPD1 Arg229Pro — A Rare Genetic Switch for Severe Infant Triglycerides

Glycerol-3-phosphate dehydrogenase 1 (GPD1) is a cytoplasmic enzyme that sits at a metabolic crossroads: it converts dihydroxyacetone phosphate (DHAP) into glycerol-3-phosphate (G3P), a building block required for triglyceride synthesis. When GPD1 fails, G3P accumulates in hepatocytes, and the liver converts the excess into triglycerides — flooding the blood with fat at levels that can exceed ten times the normal upper limit. The rs199673455 variant (c.686G>C, p.Arg229Pro) replaces a conserved arginine at position 229 of the GPD1 protein with a rigid proline residue, disrupting the enzyme's structure and abolishing its activity.

The Mechanism

GPD1 catalyses a reversible [NAD+/NADH-linked redox reaction | NAD+ is nicotinamide adenine dinucleotide, the cell's primary electron carrier; NADH is its reduced form] that links glycolysis to lipid synthesis. In the liver, G3P derived from this reaction is the essential backbone onto which fatty acids are esterified to make triglycerides. When GPD1 is inactive, two things happen simultaneously: G3P rises (because the enzyme cannot drain it) and DHAP falls (because the back-reaction stalls). The net effect is excess substrate flowing into [triglyceride synthesis | via the glycerol-3-phosphate pathway, where G3P is successively acylated by GPAT and AGPAT enzymes before becoming a diacylglycerol and finally triacylglycerol] at a rate far beyond the liver's capacity to export them as VLDL particles.

Basel-Vanagaite et al. 201211 Basel-Vanagaite et al. 2012
Transient infantile hypertriglyceridemia, fatty liver, and hepatic fibrosis caused by mutated GPD1. Am J Hum Genet. demonstrated this directly: expression of mutant GPD1 in HepG2 liver cells significantly increased triglyceride secretion compared to cells expressing wild-type GPD1 (p=0.01). The arg229 residue targeted by the Arg229Pro variant is highly conserved across vertebrates, indicating it is critical for catalysis or structural stability. Proline's cyclic side chain is uniquely rigid — its introduction into a helical or loop region that normally accommodates arginine typically breaks local protein folding.

The Evidence

The pathogenicity of Arg229Pro (c.686G>C) was established by Joshi et al. 201422 Joshi et al. 2014
A compound heterozygous mutation in GPD1 causes hepatomegaly, steatohepatitis, and hypertriglyceridemia. Eur J Hum Genet. in a Caucasian female infant who presented at age 5 months with abdominal enlargement present since birth, failure to thrive, vomiting, and hepatomegaly extending 2 cm below the umbilicus. Plasma triglycerides measured 9.48 mmol/L (normal: 0.57–1.47 mmol/L) — approximately 6.5 times the upper limit. Liver biopsy showed diffuse macro- and microvesicular steatosis consistent with non-alcoholic steatohepatitis. The proband carried the Arg229Pro allele (c.686G>C, inherited from the mother alongside a paternal GPD1 deletion) in compound heterozygosity. GPD1 protein was completely absent on western blot of liver tissue.

The founding cohort from Basel-Vanagaite et al. 201233 Basel-Vanagaite et al. 2012 included ten affected children from three consanguineous Bedouin families with a homozygous splice site mutation, confirming autosomal recessive inheritance. In that cohort, liver biopsies at 2.4 and 4.5 years of age showed macro- and microvesicular fatty change with fibrotic deposition. A large retrospective case series of 31 patients by Wang et al. 202244 Wang et al. 2022
Clinical characteristics and variant analyses of transient infantile hypertriglyceridemia related to GPD1 gene. Front Genet. found that 96.8% of patients had hypertriglyceridemia (median 3.1 mmol/L, range 1.9–70.6), 93.5% had hepatomegaly, 100% had fatty liver, and 66.7% had hepatic fibrosis. Critically, triglycerides followed a U-shaped trajectory: levels fell sharply from the infantile peak toward normal, but rebounded in many patients after approximately 50 months of age. Only 30% of followed children achieved normal triglycerides by the last measurement.

Dionisi-Vici et al. 201655 Dionisi-Vici et al. 2016
Expanding the molecular diversity and phenotypic spectrum of glycerol-3-phosphate dehydrogenase 1 deficiency. J Inherit Metab Dis. documented persistent hypertriglyceridemia into adulthood in one patient at age 30 years, confirming that the infantile designation "transient" overstates how completely lipid levels normalize in all individuals. Phenotypic heterogeneity is substantial: additional presentations include fasting hypoglycemia, insulin resistance, obesity, and short stature, as documented in Li et al. 201766 Li et al. 2017.

Practical Actions

For homozygous or compound heterozygous individuals, the primary dietary intervention is a low-fat diet with substitution of long-chain dietary fat by medium-chain triglycerides77 medium-chain triglycerides
MCTs are fatty acids with 6–12 carbons; unlike long-chain fats, they are absorbed directly into portal blood without requiring chylomicron packaging, bypassing the triglyceride synthesis step that GPD1 feeds into. The Joshi 2014 case demonstrated improved growth velocity on a high-calorie, low-fat diet with MCT supplementation. The Wang 2022 series confirmed low-fat MCT-rich nutrition as the standard dietary approach. When triglycerides remain severely elevated (above 5.6 mmol/L/500 mg/dL), fenofibrate has been used in reported cases with benefit. Prescription omega-3 fatty acids (icosapentaenoic acid, 4 g/day) significantly reduce severe hypertriglyceridemia and may be considered as adjunct therapy.

For heterozygous carriers — including parents of affected infants — current evidence shows no clinical manifestations at baseline. However, one case report identified a heterozygous GPD1 variant in an adult with recurrent hypertriglyceridemia-associated pancreatitis triggered by a high-fat diet and heavy smoking, suggesting that heterozygous carriers may be susceptible to hypertriglyceridemia when exposed to strong environmental precipitants (excessive dietary fat, alcohol, uncontrolled diabetes). Fasting lipid panels at baseline and after major lifestyle changes are reasonable.

Interactions

GPD1 deficiency operates through the glycerol-3-phosphate pathway, which converges with other triglyceride-raising mechanisms. Variants in lipoprotein lipase (LPL, rs328), apolipoprotein C-III (APOC3), and ANGPTL3 regulate the clearance of triglyceride-rich lipoproteins. In a compound-heterozygous individual who also carries a common triglyceride-raising variant such as those in LPL or APOC3, residual hypertriglyceridemia in adulthood could be exacerbated substantially. This is not documented in GPD1-specific literature but is a plausible pathway interaction worth noting in lipid panel interpretation.

Nutrient Interactions

dietary fat altered_metabolism
medium-chain triglycerides increased_need

Genotype Interpretations

What each possible genotype means for this variant.

GG Normal

No GPD1 Arg229Pro variant — standard triglyceride processing

You carry two copies of the common G allele at this position. The Arg229Pro variant is exceptionally rare — the C allele is found at a frequency of approximately 3 in 10,000 chromosomes and effectively zero in most ancestral populations tested. Your GPD1 enzyme at this residue functions normally; your triglyceride metabolism is not affected by this specific variant. Familial or environmental causes should be considered if triglyceride levels are elevated.

CG Carrier Carrier

Heterozygous carrier of the GPD1 Arg229Pro variant — typically no symptoms, but monitor lipids under metabolic stress

GPD1 Arg229Pro (c.686G>C) replaces a conserved arginine with a rigid proline at position 229 of the enzyme, disrupting its catalytic efficiency or structural integrity. In the heterozygous state, one functioning GPD1 allele typically provides sufficient enzyme activity for normal hepatic triglyceride handling. However, hepatic GPD1 activity in heterozygotes may be reduced to approximately 50% of normal — which could become rate-limiting under conditions of extreme dietary fat load or secondary lipid-raising conditions (uncontrolled type 2 diabetes, hypothyroidism, alcohol excess, or obesity-driven insulin resistance). Current evidence for symptomatic heterozygotes is limited to isolated case reports and should not be overstated.

If you are a parent of a child diagnosed with GPD1 deficiency, your carrier status means each future pregnancy has a 25% chance of an affected child, 50% chance of another carrier, and 25% chance of a non-carrier. Genetic counseling is recommended before further pregnancies.

CC GPD1 Deficient Homozygous

Homozygous GPD1 Arg229Pro — transient infantile hypertriglyceridemia with hepatic involvement

Homozygous GPD1 deficiency abolishes the enzyme's capacity to drain glycerol-3-phosphate (G3P) from the liver. The resulting G3P surplus drives uncontrolled hepatic triglyceride synthesis at a rate far exceeding the liver's export capacity as VLDL. Plasma triglycerides in the reported compound heterozygous and homozygous cases have ranged from 1.9 to 70.6 mmol/L (168 to 6,250 mg/dL). Hepatomegaly is present in over 93% of cases; hepatic fibrosis occurs in approximately two-thirds. Very high triglycerides (>11.3 mmol/L / 1,000 mg/dL) carry significant risk of acute pancreatitis, a life-threatening complication.

Long-chain dietary fat substantially worsens the phenotype because its metabolism requires G3P for triglyceride esterification in enterocytes and hepatocytes alike. Medium-chain triglycerides (MCTs) bypass this step, as they are absorbed via portal circulation and oxidized directly in the mitochondria without requiring G3P re-esterification. This is the mechanistic rationale for the MCT-based dietary approach used in reported cases.

Triglyceride trajectories follow a U-shaped pattern in most children: severe in infancy, improving toward (but not always reaching) normal by age 4–5 years, then frequently rising again. Long-term hepatic outcomes are variable — cirrhosis has been reported in a minority of cases.

Note: rs199673455 also segregates a second rare alternate allele, G>A (p.Arg229Gln), documented in compound heterozygosity with a GPD1 deletion in the landmark 2014 case report. A CC genotype at this position specifically reflects homozygosity for the Arg229Pro allele. Compound heterozygosity with other GPD1 mutations (including G>A at this same position) also causes equivalent disease.